N-Arachidonoyl Dopamine-d₈

N-Arachidonoyl dopamine-d₈ is intended for use as an internal standard for the quantification of N-arachidonoyl dopamine (Item No. 90057) by GC- or LC-MS. Several different arachidonoyl amino acids, including NADA, have been isolated and characterized from bovine brain.¹ NADA is the amide of the neurotransmitter dopamine and arachidonic acid. NADA is a CB₁-selective cannabinoid agonist, inducing the typical tetrad of hypothermia, analgesia, catalepsy, and hypomotility in rats which exceeds that of anandamide (AEA).² NADA is a full agonist at the vanilloid receptor 1, but is inactive on the dopaminergic D₁ and D₂ receptors. NADA is also a potent inhibitor (IC₅₀ = 0.25 µM) of the proliferation of MCF-7 breast carcinoma cells. Recent reports of NADA’s endothelium-dependent vasodilation indicate that some of its cannabinergic activities antagonized by SR141716A may be non-CB₁/CB₂ dependent.³

WARNING This product is not for human or veterinary use.

1. Huang, S.M., Bisogno, T., Petros, T.J., et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. The Journal of Biological Chemisty 276(46), 42639-42644 (2001).

2. Bisogno, T., Melck, D., Bobrov, M.Y., et al. N-acyl-dopamines: Novel synthetic CB₁ cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351(Pt 3), 817-824 (2001).

3. Randall, M., and Maxey, K.M. Personal Communication. (2003).

Kantae, V., Ogino, S., Noga, M., et al. Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. J. Lipid. Res. 58(3), 615-624 (2017).